DELRAY BEACH, Fla., Oct. 7, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Active Pharmaceutical Ingredients (API) Market is projected to reach USD 199.42 billion by 2031 from USD 149.02 billion in 2026, at a CAGR of 6.0% during the forecast period.

Browse 747 market data tables and 61 figures spread through 544 pages and an in-depth TOC on "Active Pharmaceutical Ingredients (API) Market - Global Forecast to 2031"

Active Pharmaceutical Ingredients (API) Market Size & Forecast:

- Market Size Available for Years: 2026–2031

- 2026 Market Size: USD 149.02 billion

- 2031 Projected Market Size: USD 199.42 billion

- CAGR (2026–2031): 6.0%

Active Pharmaceutical Ingredients (API) Market Trends & Insights:

- North America accounted for the largest share, 43.1%, of the active pharmaceutical ingredients (API) market in 2025. This dominance is driven by the presence of established pharmaceutical and API manufacturers, strong pharmaceutical R&D activities, increasing demand for innovative and complex medicines, and growing investments in domestic pharmaceutical manufacturing and supply chain resilience.

- Traditional APIs accounted for the largest share of 78.3% of the active pharmaceutical ingredients (API) market in 2025. This dominance is driven by their widespread use in generic and branded medicines, established manufacturing capabilities, broad applications across therapeutic areas, and consistent demand for pharmaceutical products.

- Pharmaceutical companies accounted for the largest share of 45.5% of the active pharmaceutical ingredients (API) market in 2025. This dominance is driven by rising pharmaceutical production, growing demand for APIs for drug development and manufacturing, increasing investment in research and development, and the growing development of innovative and complex medicines.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=263

The market is driven by the increasing demand for complex APIs, including high-potency APIs, peptides, and oligonucleotides, supported by the growing need for innovative and specialized pharmaceutical therapies. In addition, government incentives and supply chain reshoring initiatives are encouraging investments in domestic API manufacturing capabilities and strengthening supply security. The increasing adoption of advanced manufacturing technologies and the rising demand for APIs used in novel drug formulations are further supporting market growth. The growing pharmaceutical and biotechnology industries, coupled with the increasing need for effective treatments for chronic and complex diseases, are also contributing to the expansion of API manufacturing and consumption worldwide.

The API market has witnessed significant technological and manufacturing advancements that are reshaping the pharmaceutical manufacturing landscape. The adoption of continuous manufacturing has enabled API producers to improve process efficiency, enhance quality control, and achieve more consistent production, while advanced process analytical technologies are enabling real-time monitoring of critical manufacturing parameters. The increasing use of artificial intelligence, automation, and digital process optimization is further supporting predictive process control, quality management, and operational efficiency. In addition, the development of modular and high-containment manufacturing facilities is enabling manufacturers to handle complex and highly potent APIs more safely and efficiently. Regulatory initiatives are also supporting the adoption of advanced manufacturing technologies, with the US FDA promoting technologies such as continuous manufacturing, distributed manufacturing, and AI through its advanced manufacturing programs. These developments are encouraging API manufacturers to invest in advanced production capabilities while improving manufacturing flexibility, product quality, and supply-chain resilience.

By synthesis, the synthetic APIs segment held the largest share of the active pharmaceutical ingredients (API) market in 2025.

By synthesis, the active pharmaceutical ingredients (API) market is segmented into synthetic APIs and biotech APIs. In 2025, synthetic APIs accounted for the largest market share of 78.6%. This is primarily due to the widespread use of synthetic APIs in the production of generic and innovative medicines across various therapeutic areas. The established manufacturing infrastructure, well-developed synthesis processes, and broad applicability of synthetic APIs across small-molecule drug development further support the dominance of this segment in the market.

By drug, the prescription drugs segment held the largest share of the active pharmaceutical ingredients (API) market in 2025.

By drug, the active pharmaceutical ingredients (API) market is segmented into prescription drugs and over-the-counter drugs. In 2025, prescription drugs accounted for the largest market share of 89.9%. This is primarily due to the widespread use of prescription medicines for the treatment of chronic and complex diseases, including oncology, diabetes, cardiovascular diseases, and other therapeutic conditions. The increasing prevalence of chronic diseases, growing demand for innovative and specialized medicines, and rising pharmaceutical research and development activities further support the dominance of the prescription drugs segment in the market.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=263

By region, North America accounted for the largest share of the active pharmaceutical ingredients (API) market in 2025.

In 2025, North America held the largest share of the active pharmaceutical ingredients (API) market, accounting for 43.1% of the global market. This is supported by a well-established pharmaceutical industry, the presence of major pharmaceutical and API manufacturers, increasing demand for innovative and complex medicines, and strong investments in domestic pharmaceutical manufacturing. The US leads the region in pharmaceutical research & development, advanced drug development, and production of high-value and complex APIs. The presence of major pharmaceutical companies, contract manufacturing organizations, and specialized API manufacturers continues to drive demand for API products. Ongoing investments in advanced manufacturing technologies, domestic production capabilities, and supply chain resilience are further supporting market growth in North America.

Key Players

Leading players in the Active Pharmaceutical Ingredients companies include Pfizer (US), Divi's Laboratories Limited (India), Asymchem (China), Cipla (India), and Evonik (Germany), among others.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=263

Active Pharmaceutical Ingredients (API) Market - Investment & funding +Merger & Acquisition

Investment Funding Context

The active pharmaceutical ingredient (API) market is witnessing increasing investment, driven by efforts to strengthen pharmaceutical supply chains, expand domestic manufacturing, and build capabilities for complex and high-value drug substances. Investment activity is increasingly focused on capacity expansion, advanced synthesis, high-potency APIs, peptides, and supply-chain localization. For instance, in August 2025, AbbVie (US) announced a USD 195 million investment to expand API manufacturing at its North Chicago facility, supporting current and next-generation medicines across neuroscience, immunology, and oncology. Similarly, in October 2025, Cambrex (US) announced a USD 120 million investment to expand API manufacturing capacity and strengthen peptide manufacturing capabilities in the US. Government initiatives are also supporting investments in critical APIs, KSMs, and drug intermediates. These developments highlight the growing strategic importance of localized, scalable, and technologically advanced API manufacturing.

Revenue Shift Context

The active pharmaceutical ingredient (API) market is witnessing a gradual revenue shift from high-volume, commoditized APIs toward higher-value products such as high-potency APIs (HPAPIs), peptide APIs, complex small molecules, and specialty APIs. The global API market is projected to increase from USD 149.02 billion in 2026 to USD 199.42 billion by 2031, at a CAGR of 6.0%, with a growing share of revenue expected from complex and differentiated drug substances. Conventional generic APIs continue to represent an important revenue base; however, oncology APIs, highly potent compounds, peptides, and APIs requiring specialized manufacturing technologies are gaining greater commercial importance. Increasing pharmaceutical R&D activity, growth in biologics and targeted therapies, supply-chain localization, and outsourcing to specialized API manufacturers and CDMOs are further shifting revenue toward higher-value, technically complex API manufacturing services.

Mergers and Acquisitions

Mergers and acquisitions in the active pharmaceutical ingredient (API) market are being driven by the need to broaden API portfolios, strengthen complex chemistry and manufacturing capabilities, expand geographic presence, and improve access to high-growth areas such as high-potency APIs (HPAPIs), peptide APIs, specialty APIs, and advanced intermediates.

ACTIVE PHARMACEUTICAL INGREDIENT (API) MARKET: MERGERS AND ACQUISITIONS, JANUARY 2023–AUGUST 2026

Company Revenue Share Details

The top five players collectively account for approximately 2.8–3.7% of the global active pharmaceutical ingredients (API) market, indicating a highly fragmented and competitive landscape. This reflects the presence of numerous global and regional API manufacturers, specialty API suppliers, CDMOs, and pharmaceutical companies with captive API manufacturing capabilities. Key market participants include Pfizer (US), Divi's Laboratories Limited (India), Asymchem (China), Cipla (India), and Evonik (Germany).